ALTO NEUROSCIENCE, INC. reports a Return on Equity (ROE) of -30.53%.

What is ANRO's dividend yield?

ALTO NEUROSCIENCE, INC. offers a dividend yield of 0.00%.

What is ANRO's Quality Score?

Our AI rates ANRO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ANRO?

Our AI Timing Score for ANRO is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ANRO belong to?

ALTO NEUROSCIENCE, INC. is classified under the Healthcare >> Biotechnology sector on the NYSE exchange

ANRO (NYSE) Stock Analysis | ALTO NEUROSCIENCE, INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ANRO AI Analysis Summary

Our AI summary for ANRO: ALTO NEUROSCIENCE, INC. (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -30.53%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ANRO

ALTO NEUROSCIENCE, INC.

US:NYSE STOCK Healthcare >> Biotechnology News 65

USD 27.07

-1.56 (-5.45%) Day Change

Watchlist Portfolio Compare Chart

0.08

D/E

-30.5%

ROE

-26.9%

ROA

0.00%

Div Yield

ALTO NEUROSCIENCE, INC.
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 27.07 Price -1.56 (-5.45%) Day Change	NEWS SCORE: 65

ANRO, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	65
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	27.07
PBV / Sector	4.13 / 5.20
Earning Per Share	-2.00

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	14.38 M GREAT
Average 1W Daily Value	9.08 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-26.90 / 27.02
ROA Average (%) / Sector	-38.43 / -368.17
ROA Change Average (%) / Sector	-15.75 / 5,404.12
ROE (%) / Sector	-30.53 / 3.47
ROE Average (%) / Sector	1.97 / 6.51
ROE Change Average (%) / Sector	-58.43 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:28
Symbol	ANRO
Name	ALTO NEUROSCIENCE, INC.
Sector	Healthcare >> Biotechnology
Market	NYSE
Listed Shares	35.09 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,004.74 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 650 Castro Street, Mountain View, CA, United States, 94041

Phone: 650 200 0412

Website: https://www.altoneuroscience.com

Employees: 68

Sector: Healthcare >> Biotechnology

Description: Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.